Company Insights

ABCL customer relationships

Explore interactive graphBrowse insights index

ABCL customers relationship map

AbCellera Biologics (ABCL): Partnership map, revenue posture, and investor implications

AbCellera operates a commercial antibody-discovery platform that monetizes through research and engineering services, multi-year collaboration and license agreements, milestone receipts, and downstream royalties from partnered products. The company’s business model is services-led and partner-dependent: it provides discovery capabilities and hands off leads to large pharma partners under agreements that pay upfronts, R&D fees and potential milestones and royalties (AbCellera 2025 Form 10‑K). For investors, value inflection points are partner clinical readouts, milestone timing, and royalty realization; litigation settlements and license payments can be material to near-term cash flow. Learn more at NullExposure.

How AbCellera sells value: commercial posture, concentration and criticality

AbCellera’s operating model is contracting and partner-centric rather than product commercialization. The company records the majority of revenue from scientific and engineering research and testing performed in Vancouver, British Columbia, signaling a services-first revenue mix and delivery concentration in one geography (2025 Form 10‑K). AbCellera structures deals as multi-target, multi-year collaborations with large-cap pharma customers (Pfizer, Novartis, Gilead, Eli Lilly, Moderna, Regeneron, AbbVie), which creates both concentration risk and high dependency on partner pipelines for upside. Where partners commercialize programs (for example, bamlanivimab with Lilly), AbCellera captures milestone and royalty economics that materially change revenue mix and margins (10‑K, FY2025; company and press reports).

  • Company-level signals from filings also highlight payor/government exposure around commercialization and reimbursement dynamics, and the filing states coverage/reimbursement from government health authorities is an important variable for product success (2025 Form 10‑K).
  • The firm explicitly notes that it currently derives the majority of revenue from R&D and testing services in Vancouver, confirming a services-dominant operational profile (2025 Form 10‑K).

If you want a consolidated view of AbCellera’s counterparty map and how each relationship drives value, read on or visit NullExposure for supporting documentation and datasets.

Customer map — one-line takes for every relationship in the source results

  • Eli Lilly and Company (LLY / Eli Lilly) — Longstanding partner: AbCellera enabled rapid discovery of bamlanivimab and has a multi-target, multi-year collaboration spanning immunology, cardiovascular and neuroscience; this relationship illustrates AbCellera’s role as a primary discovery engine (AbCellera 2025 Form 10‑K; Goldman Sachs conference remarks, FY2026).
  • AbbVie Inc. (ABBV / AbbVie) — Multi-target, multi-year oncology collaboration listed in the 2025 Form 10‑K, representing another large pharmabiotech customer for discovery services (AbCellera 2025 Form 10‑K).
  • Bruker Corporation (BRKR / Bruker) — Resolved patent litigation with a settlement and license that delivers a US$36 million upfront payment plus ongoing royalties tied to Bruker’s Beacon Optofluidic platform; this is a one-time cash inflow and recurring royalty stream (PharmiWeb press release, Dec 18, 2025; TradingView coverage, FY2025–FY2026).
  • Autolus Therapeutics plc (AUTL / Autolus) — Single-target cell therapy collaboration (CAR‑T) noted in the 2025 Form 10‑K, reflecting AbCellera’s engagement with cell therapy developers (AbCellera 2025 Form 10‑K).
  • Biogen Inc. (BIIB / Biogen) — Single-target neuroscience collaboration documented in the 2025 Form 10‑K, adding neuro-focused discovery work to AbCellera’s roster (AbCellera 2025 Form 10‑K).
  • Teva Pharmaceutical Industries Ltd. (TEVA / Teva) — Partner-led neuroscience program in early phase development listed in the 10‑K, demonstrating relationships with large generics/innovator firms (AbCellera 2025 Form 10‑K).
  • Denali Therapeutics Inc. (DNLI / Denali) — Partner-led neurology program (TAK‑920/DNL919 Phase 1/2) referenced in the 10‑K, a mid-sized partner relationship for neurological targets (AbCellera 2025 Form 10‑K).
  • Regeneron Pharmaceuticals, Inc. (REGN / Regeneron) — Up to four targets under a multi-year arrangement, showing AbCellera’s connection to major biologics developers (AbCellera 2025 Form 10‑K).
  • Kodiak Sciences Inc. (KOD / Kodiak Sciences) — Multi-target, multi-year ophthalmology collaboration listed in the 10‑K, reflecting subspecialty partnerships (AbCellera 2025 Form 10‑K).
  • Moderna, Inc. (MRNA / Moderna) — Agreement for up to six targets focused on RNA‑encoded antibodies, coupling AbCellera discovery with mRNA delivery modalities (AbCellera 2025 Form 10‑K).
  • Novartis AG (NVS / Novartis) — Multi-target, up to 10 targets, multi-year collaboration cited in the 10‑K, signaling one of the larger strategic discovery relationships (AbCellera 2025 Form 10‑K).
  • Gilead Sciences, Inc. (GILD / Gilead) — Agreement covering eight targets and multi-year work, indicating engagement in infectious disease and other indications (AbCellera 2025 Form 10‑K).
  • IGM Biosciences, Inc. (IGMS / IGM) — Multi-target, multi-year oncology and immunology collaboration captured in the 10‑K, an example of biotech-scale partnerships (AbCellera 2025 Form 10‑K).
  • Incyte Corporation (INCY / Incyte) — Undisclosed oncology program noted in the 10‑K, signifying additional oncology customer relationships (AbCellera 2025 Form 10‑K).
  • Pfizer Inc. (PFE / Pfizer) — Multi-target, multi-year program focused on membrane proteins, present in the 10‑K and representing a major pharma client (AbCellera 2025 Form 10‑K).
  • Prelude Therapeutics (PRLD / Prelude) — Up to five targets in oncology under a multi-year arrangement, per the 10‑K (AbCellera 2025 Form 10‑K).
  • Rallybio Corporation (RLYB / Rallybio) — Up to five targets across rare metabolic disorder and undisclosed areas, documented in the 10‑K (AbCellera 2025 Form 10‑K).
  • Everest Medicines Ltd. — Up to 10 targets in oncology and other areas listed in the 10‑K, an international partner relationship (AbCellera 2025 Form 10‑K).
  • Abdera Therapeutics Inc. (ABDR / Abdera) — Multiple targets and a Phase 1 program (ABD‑147), indicating early-stage partnered programs (AbCellera 2025 Form 10‑K).
  • GigaGen, Inc. (GIGA / GigaGen) — GIGA‑564 Phase 1 program under Trianni license noted in the 10‑K, representing collaboration through antibody libraries (AbCellera 2025 Form 10‑K).
  • Arsenal Bio (ARSNL / Arsenal Bio) — AB‑2100 Phase 1/2 oncology program under Trianni license, per the 10‑K (AbCellera 2025 Form 10‑K).
  • Invetx, Inc. (INVTX / Invetx) — Multi-target, multi-year animal‑health program and pivotal studies with Dechra, cited in the 10‑K and presenting non-human revenue channels (AbCellera 2025 Form 10‑K).
  • Empirico Inc. (EMP / Empirico) — Agreement for two additional targets (undisclosed), reflecting smaller biotech partnerships (AbCellera 2025 Form 10‑K).
  • Tachyon Inc. (TACH / Tachyon) — Single-target oncology program recorded in the 10‑K, another early-stage partner (AbCellera 2025 Form 10‑K).
  • Angios (ANGIO / Angios) — Multi-target, multi-year ophthalmology collaboration noted in the 10‑K (AbCellera 2025 Form 10‑K).
  • NovaRock Biotherapeutics Inc. (NOVA / NovaRock) — NBL‑012 Phase 1 (paused) in dermatology/gastrointestinal/immunology under Trianni license, per the 10‑K (AbCellera 2025 Form 10‑K).
  • Dechra Pharmaceuticals (DPH / Dechra) — Partner-led pivotal animal-health studies with Invetx and Dechra, demonstrating veterinary applications of the platform (AbCellera 2025 Form 10‑K).
  • RQ Biotechnology Ltd. (RQBIO / RQ Biotechnology) — Up to three targets in infectious disease under a multi-year arrangement, as shown in the 10‑K (AbCellera 2025 Form 10‑K).
  • EQRx, Inc. (EQRX / EQRx) — Multi-target, multi-year oncology and immunology collaboration initially signed in 2021 and captured in the 10‑K (AbCellera 2025 Form 10‑K).

What the relationship map implies for investors

  • Concentration and counterparty exposure: AbCellera’s revenue depends on a relatively concentrated set of large pharma collaborations; successful clinical progress at partners materially drives AbCellera’s revenue and valuation (2025 Form 10‑K).
  • Services-to-royalty transition risk/reward: The company’s current services-heavy mix (R&D/testing) creates predictable near-term revenue, while milestone and royalty capture from partner commercial launches is the primary route to scalable, higher-margin revenue (10‑K).
  • Near-term cash levers: The Bruker settlement (US$36M upfront plus royalties) is a tangible cash inflow and reduces near-term free-cash-flow pressure while internal programs remain precommercial (PharmiWeb/SimplyWall/TradingView coverage, FY2025–FY2026).
  • Payor and regulatory exposure: Filings flag government payor coverage and reimbursement as material to downstream product economics, a classic commercialization risk for partners and therefore for AbCellera’s royalty potential (2025 Form 10‑K).

Investor actionables and monitoring plan

Monitor partner clinical milestones (Lilly, Moderna, Pfizer, Novartis, Gilead, Regeneron), quarterly revenue breakdowns showing services vs. milestone/royalty mix, and royalty receipts tied to the Bruker settlement. For due diligence, cross-check the 2025 Form 10‑K for contract terms and the December 2025 Bruker press release for settlement mechanics. For further analysis and consolidated counterparty scoring, visit NullExposure.

Bold takeaways: AbCellera is a services-first discovery engine whose valuation rerates on partner clinical success and realized royalty streams; the Bruker settlement provides immediate cash relief while multi-year pharma collaborations remain the principal path to durable, scalable revenue.

Join our Discord